Larazotide: the leaky-gut peptide that failed its Phase 3 trial

Larazotide has quietly become a fixture of the “leaky gut” corner of the peptide world, sold and discussed as an oral fix for a permeable intestinal lining. That framing buries the far more interesting truth: larazotide is a real investigational drug with a genuine, decade-long clinical program in celiac disease — one that produced encouraging mid-stage data and then missed the primary endpoint of its pivotal Phase 3 trial. It is not an approved medicine, and the supplement-style use for generic “gut health” runs well ahead of anything the evidence supports.

What it actually is

Larazotide acetate — originally coded AT-1001 — is a synthetic peptide just eight amino acids long. Unlike most peptides in the recovery scene, it is taken orally, as a capsule swallowed before meals, and it is designed to act locally in the gut rather than being absorbed into the bloodstream. Its first-in-human study, a single-dose proof-of-concept in celiac subjects, established that it was tolerated and reported early signals on intestinal permeability and gluten-induced symptoms.^[1] If you are new to how these molecules are classified and why an eight-residue chain counts as a “peptide drug,” our primer on what peptides actually are is a useful backdrop.

The mechanism: tightening the gut’s seams

The lining of your gut is a single layer of cells, and the spaces between those cells are sealed by protein complexes called tight junctions. When those seals loosen, larger molecules can slip through the gaps — the phenomenon loosely marketed as “leaky gut.” A protein called zonulin is a key regulator of that loosening: released in response to certain triggers (including gluten in susceptible people), it prises the junctions open and increases intestinal permeability.^[2] Larazotide is designed to work as a zonulin antagonist — it counteracts that loosening and helps keep the junctions cinched shut, reducing the passage of gluten fragments across the barrier. That is a much more specific, receptor-adjacent mechanism than the broad “repair everything” story told about peptides like BPC 157, and it is why larazotide was developed for one disease where barrier leakiness is central rather than as a general-purpose tonic.

The real clinical program: celiac disease

Larazotide advanced furthest as an adjunct to a gluten-free diet — not a replacement for it. The problem it targeted is real and common: many people with celiac disease stay symptomatic despite scrupulously avoiding gluten, likely because trace exposures still breach a leaky barrier. In a gluten-challenge trial, larazotide reduced markers of gluten-induced injury and symptoms compared with placebo, supporting the barrier hypothesis.^[3] The high-water mark was a Phase 2b study, CeliAction, in 342 adults who remained symptomatic on a gluten-free diet: the 0.5 mg dose significantly reduced celiac symptoms versus placebo, and — notably — the two higher doses did not, an inverted dose-response that would later prove important.^[4] On the strength of that signal, larazotide became the most clinically advanced drug candidate in celiac disease and earned FDA Fast Track designation.

The Phase 3 that failed

This is the part the supplement marketing leaves out. The pivotal Phase 3 trial, CeDLara, tested larazotide in symptomatic celiac patients on a gluten-free diet, with a primary endpoint based on patient-reported abdominal symptom severity over 12 weeks. In June 2022, after a pre-specified interim analysis of roughly half the target enrollment, the sponsor (9 Meters Biopharma) announced that the study would not meet its primary endpoint and that continuing was not justified — the number of additional patients needed to show a benefit was simply too large.^[5] The trial was halted. A drug that had looked promising in Phase 2 did not hold up under the larger, more rigorous Phase 3 test — the single most important fact about larazotide’s efficacy, and a textbook reminder that mid-stage signals often do not survive.

The consumer gap

Larazotide is investigational. It is not approved by the FDA — or any major regulator — for celiac disease, “leaky gut,” or anything else, and its pivotal trial failed. Yet it is sold and swapped in the peptide and gut-health gray market for exactly the broad “heal your intestinal barrier” claims that were never tested, let alone proven. The molecule’s legitimate evidence lives entirely within a narrow, gluten-specific context in people with diagnosed celiac disease; extrapolating that to general permeability, food sensitivities, or autoimmunity is not supported by the data. As with other repurposed research peptides such as thymosin alpha-1, unapproved products carry the added, molecule-independent risks of contamination, mislabeling and mis-dosing.

The honest bottom line

Larazotide is a legitimate scientific story with a disappointing ending: a well-designed oral peptide, a coherent tight-junction mechanism, real positive Phase 2 data — and a Phase 3 trial that missed. That arc makes it more interesting than most “gut peptides,” not less. But interesting is not the same as proven, and a failed pivotal trial is not a foundation for buying an unregulated capsule to fix a vaguely defined “leaky gut.” If larazotide ever earns a place in medicine, it will be through a new, successful trial — not through the supplement channel it currently occupies. This article is educational and is not medical advice; decisions about celiac disease or gut symptoms belong with a qualified clinician.